Keith A. is a social critic and author, currently working as a freelancer. He has previously held positions as a senior editor at Salon.com and as the editor-in-chief of The Bold Italic. Keith's work covers a wide range of topics, including politics, social issues, healthcare, and business, and his articles have been featured in numerous publications such as Nature Portfolio, Reuters, and The Lancet.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Keith A. focuses on providing practical guidance and insights in the areas of human resources, healthcare, and corporate affairs. He regularly includes data citations to support his content.
To effectively reach out to Keith A., consider offering actionable advice or relevant data that addresses topics related to physician practice management, work-life balance for professionals, tax implications for physicians, legal aspects such as the Corporate Transparency Act's impact on small businesses, and branding strategies within the healthcare industry.
Given Keith’s national focus on the United States and his coverage of specific laws like the Corporate Transparency Act, pitches should have a clear relevance to U.S.-based regulations or practices unless they present broader principles applicable across different jurisdictions.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The definitive ranking of which states are best for physicians.
The method behind our definitive list of the best states for practicing medicine.
By: Keith A. Reynolds
The monthly collection of insights from the Physicians Practice Pearls writers.
Which states have the highest taxes?
Abstract Magnons are quantized collective spin-wave excitations in magnetically ordered materials.
Abstract Axially swept light-sheet microscope in conjunction with tissue clearing enables three-dimensional morphological investigation of
By: Caroline M. Nievergelt, Adam X. Maihofer, Elizabeth G. Atkinson, Karmel W. Choi, Nikolaos P. Daskalakis, Laramie E. Duncan, Renato Polimanti, Cindy Aaronson, Ananda B. Amstadter, Soren B. Andersen, Ole A. Andreassen, Paul A. Arbisi, Allison E. Ashley-Koch
Post-traumatic stress disorder (PTSD) genetics are characterized by lower discoverability than most other psychiatric disorders. The contribution to biological understanding from previous genetic studies has thus been limited. We performed a multi-ancestry meta-analysis of genome-wide association studies across 1,222,882 individuals of European ancestry (137,136 cases) and 58,051 admixed individuals with African and Native American ancestry (13,624 cases). We identified 95 genome-wide significant loci (80 new). Convergent multi-omic approaches identified 43 potential causal genes, broadly classified as neurotransmitter and ion channel synaptic modulators (for example, GRIA1, GRM8 and CACNA1E ), developmental, axon guidance and transcription factors (for example, FOXP2, EFNA5 and
By: John Alex, Jorge, David H.,, Elouise A.,, Heidi I. L.,, Kenneth, David A., Kathryn V.,, Keith A., Kim
In vivo human neuroimaging shows that locus coeruleus (LC) integrity changes precede medial temporal tau accumulation, and jointly predict future lower cognition in older people at risk for Alzheimer’s disease. A common transcriptomic profile underlies LC’s early vulnerability to tau.
Correction: Molecular Neurodegeneration (2024) 19:29
By: Tian, Liyang, Hong, Huang, Webster, Wei, Li, Ji, Chengchi, Keith A.
Efforts to develop gene therapy for long-term treatment of neovascular disease are hampered by ongoing concerns that biologics against vascular endothelial growth factor (VEGF) inhibit both physiological and pathological angiogenesis and are therefore at elevated risk of adverse side effects. A potential solution is to develop disease-targeted gene therapy. Secretogranin III (Scg3), a unique disease-restricted angiogenic factor described by our group, contributes significantly to ocular neovascular disease. We have shown that Scg3 blockade with a monoclonal antibody Fab fragment (Fab) stringently inhibits pathological angiogenesis without affecting healthy vessels. Here we tested the therapeutic efficacy of adeno-associated virus (AAV)-anti-Scg3Fab to block choroidal neovascularization (CNV) induced by subretinal injection of Matrigel in a mouse model. Intravitreal AAV-anti-Scg3Fab significantly reduced CNV and suppressed CNV-associated leukocyte infiltration and macrophage activation. The efficacy and anti-inflammatory effects were equivalent to those achieved by positive control AAV-aflibercept against VEGF. Efficacies of AAV-anti-Scg3Fab and AAV-aflibercept were sustained over 4 months post AAV delivery. The findings support development of AAV-anti-Scg3 as an alternative to AAV-anti-VEGF with equivalent efficacy and potentially safer mechanism of action.
(833) 317-6278 
